PNS43 Have NMPA Priority Review Designations Supported Accelerated Regulatory Approval and Patient Access?

Abstract

In 2016, CFDA(the former name of the NMPA) announced a new ‘priority review’ process to address the legacy problems of the backlog of drug registration and the procrastinated marketing of new drugs. A long-awaited update to the National Reimbursement Drug List (NRDL) was completed in 2017, some new drugs with a focus on major illnesses had been added to the list. This study evaluate the NMPA priority review designations from 2016 to 2019 and how these have translated into reimbursement and patient access.